Friday, 06 Dec 2019

You are here

Frequent DMARD Discontinuations During Rheumatoid Pregnancies

A Canadian population-based study shows that pregnant women with rheumatoid arthritis (RA) frequently discontinue their DMARD medications, especially in the first trimester.

An administrative data study looked at women with RA with a singleton pregnancy who were studied for utilization of RA medications, including conventional synthetic DMARDs, biologics, glucocorticosteroids and NSAIDs.

Among 1730 pregnancies in 1301 RA women they observed substantial medication discontinuation. This was most notable in the first trimester, with the majority of RA patients discontinuing antimalarials (57.3%), azathioprine (59.1%), sulfasalazine (69.5%) and biologics (50.8%).

Discontinuation of antimalarials in the first trimester was associated with being multiparous, a higher discontinuations were seen with lower maternal age (OR 0.90; 95% CI 0.86, 0.95) and fewer rheumatology visits (OR 0.86; 0.75, 0.97). Biologic discontinuations were associated with prior adverse birth outcomes (OR 0.22; 0.05, 0.95).

The fact that RA patients frequently discontinue their DMARD and biologic medications once they become pregnant suggests a need to educate women with RA, who are planning pregnancy, on the risks of medications during pregnancy and which can be safely continued.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA Warns 15 CBD Manufacturers

Today, the U.S. Food and Drug Administration issued warning letters to 15 companies for illegally selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act).  This warning affirms that the FDA has not determined the many preparations of cannabidiol to be safe or effective.

Biologic Safety Guidelines from the British Society for Rheumatology

In the United Kingdom, NICE has looked to the British Society of Rheumatology (BSR) to develop evidence based guidance on the safe use of biologic DMARDs in patients with inflammatory arthritis. This guidance document on biologic safety covers baseline screening, monitoring, effect of co-morbidities, and when or under what circumstances biologic therapy should be interrupted.

Herpes Zoster Vaccine Update

Shingrix (GSK), the herpes zoster subunit vaccine (a two-shot series), was approved by the FDA in Fall 2018 and is currently approved for use in adults 50 years and older. Shingrix has replaced the live zoster vaccine, Zostavax (Merck) as the preferred shingles vaccine, however its use in patients with immune-mediated inflammatory diseases (IMIDs) remains a gray area.

A Focus on WOCBA (Women of Childbearing Age)

Largely because it can be difficult to do studies in pregnant women, gaps remain in the area of rheumatic disease in pregnancy. This year’s ACR highlights some important new points to consider.

Influenza Vaccine Updates And Pearls At ACR 2019

As we enter flu season it is of the utmost importance that we remember to assess our patients’ influenza vaccine status at each visit.